Literature DB >> 20044979

Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis.

Jaspreet Kaur1, Raghu Adya, Bee K Tan, Jing Chen, Harpal S Randeva.   

Abstract

Chemerin acting via its distinct G protein-coupled receptor CMKLR1 (ChemR23), is a novel adipokine, circulating levels of which are raised in inflammatory states. Chemerin shows strong correlation with various facets of the metabolic syndrome; these states are associated with an increased incidence of cardiovascular disease (CVD) and dysregulated angiogenesis. We therefore, investigated the regulation of ChemR23 by pro-inflammatory cytokines and assessed the angiogenic potential of chemerin in human endothelial cells (EC). We have demonstrated the novel presence of ChemR23 in human ECs and its significant up-regulation (P<0.001) by pro-inflammatory cytokines, TNF-alpha, IL-1beta and IL-6. More importantly, chemerin was potently angiogenic, as assessed by conducting functional in-vitro angiogenic assays; chemerin also dose-dependently induced gelatinolytic (MMP-2 & MMP-9) activity of ECs (P<0.001). Furthermore, chemerin dose-dependently activated PI3K/Akt and MAPKs pathways (P<0.01), key angiogenic and cell survival cascades. Our data provide the first evidence of chemerin-induced endothelial angiogenesis and MMP production and activity. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044979     DOI: 10.1016/j.bbrc.2009.12.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  132 in total

1.  Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim.

Authors:  Rui-jun Zhao; Hai Wang
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

Review 2.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Germline Genetic Variants and Lung Cancer Survival in African Americans.

Authors:  Carissa C Jones; William S Bush; Dana C Crawford; Angela S Wenzlaff; Ann G Schwartz; John K Wiencke; Margaret R Wrensch; William J Blot; Stephen J Chanock; Eric L Grogan; Melinda C Aldrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-15       Impact factor: 4.254

4.  Trash Talk by Fat: Chemerin as a Reactive Oxygen Species Provocateur in the Vasculature.

Authors:  Stephanie W Watts
Journal:  Hypertension       Date:  2015-07-06       Impact factor: 10.190

5.  Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions.

Authors:  Noha A Ghallab; Olfat G Shaker
Journal:  Clin Oral Investig       Date:  2016-05-10       Impact factor: 3.573

Review 6.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

7.  Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome.

Authors:  Gökhan Aksan; Sinan İnci; Gökay Nar; Korhan Soylu; Ömer Gedikli; Serkan Yüksel; Metin Özdemir; Rukiye Nar; Murat Meriç; Mahmut Şahin
Journal:  Int J Clin Exp Med       Date:  2014-12-08

Review 8.  Adipokines as a novel link between obesity and atherosclerosis.

Authors:  Hye Jin Yoo; Kyung Mook Choi
Journal:  World J Diabetes       Date:  2014-06-15

Review 9.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12

10.  Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.

Authors:  Haifeng Huang; Liping Hu; Jiancong Lin; Xiaoxiao Zhu; Weiling Cui; Wenming Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.